The convergence of nanobiotechnology and artificial intelligence (AI) is reshaping our discipline, moving it from trial-and-error experimentation toward predictive, systematically engineered approaches. AI has moved from a supporting analytic tool to a central driver of discovery and translation. At the same time, researchers are gaining finer control over nanoscale architectures and biological interfaces, a trend reflected in routine laboratory practice. Laboratory experiments are increasingly structured around machine-learning requirements, with descriptors formatted for algorithmic use and closed-loop experimentation used to shorten validation cycles. The impact is not only faster progress but also a redefinition of what counts as evidence, reproducibility, and translational readiness. A clear illustration of this transformation is the inverse design of lipid nanoparticles (LNPs) for nucleic acid delivery, where machine learning (ML) models start from desired biological outcomes and work backward to propose nanoparticle structures most likely to achieve them.

PDF (Download Full text)

Download Citation (XML)